Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$203.77 USD
-2.02 (-0.98%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $203.82 +0.05 (0.02%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
CRL 203.77 -2.02(-0.98%)
Will CRL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRL
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
CRL Stock May Benefit From New Neuroscience Research Collaboration
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
Other News for CRL
Charles River price target lowered by $1 at Baird, here's why
BlackRock Innovation And Growth Term Trust Q2 2024 Commentary
Creightons Updates Share Capital and Voting Rights
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
Charles River announces collaboration with DanubeNeuro acceleration program